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Abstract:  Saxitoxin (STX) and its 57 analogs are a broad group of natural neurotoxic 
alkaloids, commonly known as the paralytic shellfish toxins (PSTs). PSTs are the causative 
agents  of  paralytic  shellfish  poisoning  (PSP)  and  are  mostly  associated  with  marine 
dinoflagellates  (eukaryotes)  and  freshwater  cyanobacteria  (prokaryotes),  which  form 
extensive blooms around the world. PST producing dinoflagellates belong to the genera 
Alexandrium,  Gymnodinium  and  Pyrodinium  whilst  production  has  been  identified  in 
several cyanobacterial genera including Anabaena, Cylindrospermopsis, Aphanizomenon 
Planktothrix and Lyngbya. STX and its analogs can be structurally classified into several 
classes such as non-sulfated, mono-sulfated, di-sulfated, decarbamoylated and the recently 
discovered hydrophobic analogs—each with varying levels of toxicity. Biotransformation 
of  the  PSTs  into  other  PST  analogs  has  been  identified  within  marine  invertebrates, 
humans and bacteria. An improved understanding of PST transformation into less toxic 
analogs  and  degradation,  both  chemically  or  enzymatically,  will  be  important  for  the 
development  of  methods  for  the  detoxification  of  contaminated  water  supplies  and  of 
shellfish destined for consumption. Some PSTs also have demonstrated pharmaceutical 
potential  as  a  long-term  anesthetic  in  the  treatment  of  anal  fissures  and  for  chronic  
tension-type headache. The recent elucidation of the saxitoxin biosynthetic gene cluster in 
cyanobacteria  and  the  identification  of  new  PST  analogs  will  present  opportunities  to 
further explore the pharmaceutical potential of these intriguing alkaloids. 
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1. Introduction  
The  paralytic  shellfish  toxins  (PSTs)  are  a  group  of  naturally  occurring  neurotoxic  alkaloids. 
Saxitoxin (STX) is the most researched PST to date, and since its discovery in 1957 [1], 57 analogs 
have been described. The PSTs are primarily produced in detrimental concentrations during harmful 
algal  bloom  (HAB)  events  [2–5]  Over  the  last  few  decades,  HABs  have  become  more  frequent, 
intense, and span a wider global distribution, the cause of which is still under debate [3,6]. The PSTs 
can be broadly characterized as hydrophilic or hydrophobic, and can be divided into subgroups based 
on substituent side chains such as carbamate, sulfate, hydroxyl, hydroxybenzoate, or acetate. Each 
moiety then imparts a varying level of toxicity [7].  
In marine environments, PSTs are primarily produced by the eukaryotic dinoflagellates, belonging 
to the genera Alexandrium, Gymnodinium and Pyrodinium [8–10]. The toxins are passed through the 
marine food web via vector organisms, which accumulate the toxins by feeding on PST producing 
dinoflagellates without apparent harm to themselves [11,12]. These include filter feeding invertebrates 
such as shellfish, crustaceans, molluscs and also other, non-traditional vectors such as gastropods and 
planktivorous  fish  [13].  In  freshwater  environments  the  PSTs  are  produced  by  prokaryotic 
cyanobacteria belonging to the genera Anabaena, Cylindrospermopsis, Aphanizomenon, Planktothrix 
and  Lyngbya.  Cyanobacterial  PST  producing  blooms  result  in  the  contamination  of  drinking  and 
recreational water resources. In the past, high levels of toxins have been detected in the freshwater 
resources of many countries such as Australia, Brazil, USA, Mexico, Germany and China [14–22]. 
Intoxication with PSTs may result in the severe and occasionally fatal illness known as paralytic 
shellfish poisoning (PSP) or saxitoxin pufferfish poisoning (SPFP) [23–27]. This illness is caused 
when PSTs reversibly bind voltage-gated Na
+ channels in an equimolar ratio. This is mediated by the 
interaction  between  the  positively  charged  guanidinium  groups  of  STX  with  negatively  charged 
carboxyl groups at site 1 of the Na
+ channel, thereby blocking the pore (Figure 1) [28–30]. Currently, 
there is no antidote for PSP with artificial respiration and fluid therapy the only treatment available. A 
recent case of PSP involved the death of two fishermen after consumption of the filter feeder bi-valve 
Aulacomya ater in the Chilean Patagonian Fjords [26]. The threat of PSP is not only a major cause of 
concern for public health but is also detrimental to the economy. Outbreaks of PSTs often result in the 
death  of  marine  life  and  livestock,  the  closure  of  contaminated  fisheries,  while  the  continual 
expenditure required for the maintenance and running of monitoring programs, all combine to present 
a major economic burden around the world [31,32]. 
This review will focus on the structural diversity of PSTs characterized to date and the biosynthetic 
and metabolic basis for this diversity. The saxitoxin biosynthetic gene cluster (sxt) was recently identified 
in cyanobacteria, which now provides insight into the biosynthesis of STX and its analogs [33,34]. A 
specific suite of analogs can be isolated from a single PST-producing organism, which is directly a 
result of the evolution of genes present within the organism’s genome [14,33–37]. Naturally occurring Mar. Drugs 2010, 8  
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PSTs can also be precursors for extracellular metabolic or chemical transformations into new analogs. 
Knowledge of these transformations may have important implications for the detection, toxicity and 
removal  of  PSTs  from  a  contaminated  source.  Other  medicinal  uses  for  PSTs  may  become  more 
established  by  screening  the  bioactivity  of  less  toxic  analogs,  since  their  use  as  a  potential  local 
anesthetic has long been known [38,39]. The characterization of PST biosynthesis genes and their 
potential use in combinatorial biosynthesis, together with the constant discovery of novel analogs 
(either  natural  or  transformed),  is  likely  to  expand  the  possibilities  for  the  pharmaceutical  use  of 
PSTs [40,41].  
Figure 1. The proposed transmembrane arrangement of the ʱ-subunit of Na
+ channels. The 
pore is represented in red, the voltage sensors in yellow and the inactivation gate in blue. 
PSP is mediated by the interaction and blockage of Site 1 by STX. Figure adapted from [30]. 
 
2. Saxitoxin and Its Analogs, the Paralytic Shellfish Toxins 
STX is one of the most potent natural neurotoxins known. A dose of approximately 1 mg of the 
toxin from a single serving of contaminated shellfish is fatal to humans. STX was the first PST isolated 
in  pure  form  from  the  Alaskan  butter  clam,  Saxidomus  gigangteus  in  1957  [1].  Its  highly  polar 
characteristics represent poor conditions for crystallization and hampered structure elucidations for  
18 years, until the crystal structure was solved by two groups independently in 1975 [42,43]. STX is 
an alkaloid with the molecular formula C10H17N7O4 (Molecular Weight = 299) and is composed of a  
3,4-propinoperhydropurine tricyclic system. STX belongs to the large family of guanidinium-containing 
marine natural products, due to the presence of two guanidino groups which are responsible for its 
high  polarity  [44,45].  Since  its  initial  discovery,  57  naturally  occurring  STX  analogs  have  been 
identified in a number of organisms, collectively referred to as the PSTs (Table 1). Mar. Drugs 2010, 8  
 
 
2188 
Table 1. The paralytic shellfish toxins.  
N
N N
H
N
OH
R5
NH2
+
R4
+H2N
1
3
2
7
8
9
R1
R2 R3
11
12
 
Toxin  R1  R2  R3 
Ω R4  R5  Origin  Ref. 
STX  H  H  H  OCONH2  OH  Alexandrium andersoni 
A. catenella 
A. fundyense 
A. tamarense 
A. circinalis 
Aphanizomenon flos-aquae 
Aph. gracile 
Aph. issatschenkoi  
Anabaena lemmermannii 
C. raciborskii 
Gymnodinium catenatum  
Pyrodinium bahamense 
Planktothrix sp. 
[46] 
[47–49] 
[50–52] 
[53–56] 
[35,57–59]  
[60–63]  
[20,64]  
[65]  
[66]  
[16,36,67–69]  
[70–72] 
[10] 
[73] 
neoSTX  OH  H  H  OCONH2  OH  A. andersoni 
A. catenella 
A. fundyense 
A. tamarense 
Aph. flos-aquae 
Aph. gracile 
Aph. issatschenkoi 
Aph. sp. 
C. raciborskii 
G. catenatum 
P. bahamense 
[46] 
[47–49] 
[50–52] 
[53–56] 
[60–63] 
[20,64] 
[65] 
[74] 
[16,36,69] 
[70,71] 
[10] 
Mono-Sulfated     
GTX1  OH  H  OSO3
−  OCONH2  OH  A. catenella 
A. fundyense 
A. minutum 
A. tamarense 
Aph. flos-aquae 
G. catenatum 
[47–49,75,76] 
[50–52] 
[77–79] 
[53–56] 
[37] 
[9,70,72] Mar. Drugs 2010, 8  
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Table 1. Cont. 
Toxin  R1  R2  R3 
ΩR4  R5  Origin  Ref. 
Mono-Sulfated     
GTX2  H  H  OSO3
−  OCONH2  OH  A. catenella 
A. fundyense 
A. minutum 
A. ostenfeldii 
A. tamarense 
A. circinalis  
C. raciborskii 
G. catenatum 
[48,49] 
[50–52] 
[77–79] 
[80] 
[53–56] 
[35,57–59] 
[36,67] 
[9,70,72] 
GTX3  H  OSO3
−  H  OCONH2  OH  A. catenella 
A. fundyense 
A. minutum 
A. ostenfeldii 
A. tamarense 
A. circinalis  
Aph. flos-aquae 
C. raciborskii  
G. catenatum 
[47–49] 
[50–52] 
[77–79] 
[80] 
[53–56] 
[35,57–59]  
[37]  
[36,67] 
[9,70,72] 
GTX4  OH  OSO3
−  H  OCONH2  OH  A. catenella 
A. fundyense 
A. minutum 
A. tamarense 
Aph. flos-aquae 
G. catenatum 
[47–49,75,76] 
[50–52] 
[77–79] 
[53–56] 
[37] 
[9,70,72] 
GTX5 
(B1) 
H  H  H  OCONHSO3
−  OH  A. catenella 
A. fundyense 
A. tamarense 
A. circinalis 
Aph. flos-aquae  
Aph. gracile 
Aph. issatschenkoi 
G. catenatum 
P. bahamense 
[48,49,75,76] 
[50–52] 
[54,56] 
[35,57,59]  
[60,63] 
[20] 
[37,65] 
[9,71,81] 
[10] 
GTX6 
(B2) 
OH  H  H  OCONHSO3
−  OH  A. catenella 
A. fundyense 
A. ostenfeldii 
A. tamarense 
Aph. flos-aquae 
C. raciborskii 
G. catenatum 
P. bahamense 
[47,49,75,76] 
[52] 
[80] 
[54] 
[63]  
[69] 
[9,71,72,81] 
[10] Mar. Drugs 2010, 8  
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Table 1. Cont. 
Toxin  R1  R2  R3 
ΩR4  R5  Origin  Ref. 
Di-Sulfated     
C1  H  H  OSO3
−  OCONHSO3
−  OH  A. catenella 
A. fundyense 
A. ostenfeldii 
A. tamarense 
A. circinalis  
C. raciborskii 
G. catenatum 
[48,49,75,76] 
[50–52] 
[80] 
[53–56] 
[35,57–59] 
[68] 
[9,71,72,81] 
C2  H  OSO3
−  H  OCONHSO3
−  OH  A. catenella 
A. fundyense 
A. ostenfeldii 
A. tamarense 
A. circinalis  
C. raciborskii 
G. catenatum 
[48,49,75] 
[50–52] 
[80] 
[53–56] 
[35,57–59]  
[68] 
[9,71,72,81] 
C3  OH  H  OSO3
−  OCONHSO3
−  OH  A. catenella 
G. catenatum 
[48,49,75,76] 
[9,72,81] 
C4  OH  OSO3
−  H  OCONHSO3
−  OH  A. catenella 
G. catenatum 
[48,49,75,76] 
[9,72,81] 
Decarbamoylated     
dcSTX  H  H  H  OH  OH  A. catenella 
A. circinalis  
Aph. flos-aquae 
Aph. gracile 
Aph. issatschenkoi 
Aph. sp. 
C. raciborskii 
Lyngbya wollei 
G. catenatum 
P. bahamense 
[49] 
[35,59] 
[60,63] 
[20] 
[65]  
[74] 
[16,67,69]  
[82] 
[9,71,72] 
[10] 
dcneoSTX  OH  H  H  OH  OH  C. raciborskii  [69] 
dcGTX1  OH  H  OSO3
−  OH  OH  G. catenatum  [83] 
dcGTX2  H  H  OSO3
−  OH  OH  A. catenella 
A. fundyense 
A. circinalis 
G. catenatum 
L. wollei 
[49] 
[52] 
[35,57–59]  
[9,71] 
[14,82] 
dcGTX3  H  OSO3
−  H  OH  OH  A. catenella 
A. fundyense 
A. circinalis 
Aphanizomenon sp. 
L. wollei 
G. catenatum 
[49] 
[50,52] 
[35,57–59] 
[74] 
[14,82] 
[9,71] 
dcGTX4  OH  OSO3
−  H  OH  OH  G. catenatum  [83] Mar. Drugs 2010, 8  
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Table 1. Cont. 
Toxin  R1  R2  R3 
ΩR4  R5  Origin  Ref. 
Deoxy-Decarbomoylated     
doSTX  H  H  H  H  OH  G. catenatum  [9,84] 
doGTX1  OH  H  OSO3
−  H  OH  G. catenatum  [9,84] 
doGTX2  H  H  OSO3
−  H  OH  G. catenatum  [9,84] 
L. wollei toxins     
LWTX1  H  H  OSO3
−  OCOCH3  H  L. wollei  [82] 
LWTX2  H  H  OSO3
−  OCOCH3  OH  L. wollei  [82] 
LWTX3  H  OSO3
−  H  OCOCH3  OH  L. wollei  [82] 
LWTX4  H  H  H  H  H  L. wollei  [82] 
LWTX5  H  H  H  OCOCH3  OH  L. wollei  [82] 
LWTX6  H  H  H  OCOCH3  H  L. wollei  [82] 
Mono-Hydroxy-Benzoate Analogs     
GC1  H  H  OSO3
−  OCOPhOH  OH  G. catenatum  [83] 
GC2  H  OSO3
−  H  OCOPhOH  OH  G. catenatum  [83] 
GC3  H  H  H  OCOPhOH  OH  G. catenatum  [83] 
*GC4  OH  H  OSO3
−  OCOPhOH  OH  G. catenatum  [85] 
*GC5  OH  OSO3
−  H  OCOPhOH  OH  G. catenatum  [85] 
*GC6  OH  H  H  OCOPhOH  OH  G. catenatum  [85] 
Di-Hydroxy Benzoate Analogs     
ŧGC1a  H  H  OSO3
−  DHB  OH  G. catenatum  [85] 
ŧGC2a  H  OSO3
−  H  DHB  OH  G. catenatum  [85] 
ŧGC3a  H  H  H  DHB  OH  G. catenatum  [85] 
ŧGC4a  OH  H  OSO3
−  DHB  OH  G. catenatum  [85] 
ŧGC5a  OH  OSO3
−  H  DHB  OH  G. catenatum  [85] 
ŧGC6a  OH  H  H  DHB  OH  G. catenatum  [85] 
Sulfated Benzoate Analogs     
ŧGC1b  H  H  OSO3
−  SB  OH  G. catenatum  [85] 
ŧGC2b  H  OSO3
−  H  SB  OH  G. catenatum  [85] 
ŧGC3b  H  H  H  SB  OH  G. catenatum  [85] 
ŧGC4b  OH  H  OSO3
−  SB  OH  G. catenatum  [85] 
ŧGC5b  OH  OSO3
−  H  SB  OH  G. catenatum  [85] 
ŧGC6b  OH  H  H  SB  OH  G. catenatum  [85] 
Other PST Analogs     
M1  H  OH  H  OCONHSO3
−  OH  Metabolic 
transformation 
[56,81] 
M2  H  OH  H  OCONH2  OH  Metabolic 
transformation 
[56] 
M3  H  OH  OH  OCONHSO3
−  OH  Metabolic 
transformation 
[56] 
M4  H  OH  OH  OCONH2  OH  Metabolic 
transformation 
[56] 
*M5    Metabolic 
transformation 
[56] Mar. Drugs 2010, 8  
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Table 1. Cont. 
Toxin  R1  R2  R3 
ΩR4  R5  Origin  Ref. 
Other PST Analogs     
*A            Unknown  [86] 
*B            Unknown  [86] 
*C            Unknown  [86] 
*D            Unknown  [86] 
SEA  H  CCOO
−  H  OCONH2  OH  Atergatis floridus  [87] 
STX-uk  H  H  H  OCONHCH3  OH  Tetraodon cutcutia  [88] 
Zetekitoxin AB 
HN
N N
H
N
OH
OH
NH
HN
1
3
2
7
8
9
O
N
O
OH
O
O H
N
OH
OSO3H  
Atelopus zeteki  [89] 
* Not structurally characterized  
ŧ R4 group putatively assigned based on major ions obtained via MS [85] 
ΩOCONH2  O
H2N
O
 
           
ΩOCONHSO3
− 
O
HN
O
-O3S  
           
ΩOCOCH3  O
H3C
O
 
           
ΩOCOPhOH 
O
HO
O
 
           
ΩOCONHCH3 
O
N
H
O
H3C
 
           
ΩDHB: Di-hydroxyl-benzoate     
ΩSB: Sulfated-benzoate     
Usually a PST- producing organism synthesizes a characteristic suite of toxins made up of several 
PST analogs. These analogs differ in side group moieties and thus are commonly grouped according to 
these variable residues. The most commonly occurring PSTs are hydrophilic and have been studied in 
depth [7]. They may be non-sulfated, such as STX and neosaxitoxin (neoSTX), mono-sulfated, such as 
the gonyautoxins (GTXs 1–6), or di-sulfated (C1-4 toxins) [7,90]. In addition, decarbamoyl variants of 
these analogs also exist, including decarbamoyl-saxitoxins (dcSTX, dcneoSTX), decarbamoyl-gonyautoxins 
(dcGTXs  1–4),  and  the  13-deoxy-decarbamoyl  derivatives  (doSTX,  doGTX  2,3).  Three  structural 
families  of  SXT  are  classified  by  the  identity  of  the  R4  side  chain  as  either  N-sulfocarbamoyl, 
decarbamoyl, or carbamoyl, each with increasing toxicity in mammalian bioassays (Table 2) [7,9,90]. 
Recently, an increase in screening efforts, coupled with improved methods for detection and structure 
elucidation, has seen an increase in the number of new PSTs reported in the literature.  Mar. Drugs 2010, 8  
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Table 2. Relative toxicity of the paralytic shellfish toxins. Toxicity of the PSTs due to 
change in moiety is listed in descending order. Data obtained from [95]. 
Structure 
Ω  Toxin  Relative toxicity 
Φ 
HN
N N
H
N
OH
OH
NH
HN
O
N O
OH
O
O H
N
OH
OSO3H  
Zetekitoxin AB  63, 160, 580
ω 
N
N N
H
N
OH
OH
NH2
+
+H2N
R1
H H
O
H2N
O
 
Non-Sulfated   
STX 
NeoSTX 
1 
05–1.1 
N
N N
H
N
OH
OH
NH2
+
+H2N
R1
R2 R3
O
H2N
O
 
Mono-sulfated   
GTX1/4
¥ 
GTX2/3
¥ 
0.39/1.09–0.48/0.76 
0.8/0.33–0.9/0.9 
N
N N
H
N
OH
OH
NH2
+
+H2N
H
H H
HO
 
Decarbamoylated   
dcSTX 
dcNeoSTX 
dcGTX1-4 
0.43 
0.43 
0.18–0.45 
N
N N
H
N
OH
OH
NH2
+
+H2N
R1
R2 R3
O
N
H
O
-O3S
 
Di-sulfated   
C1-4  <0.01–0.14 
Ω  Refer  to  Table  1  for  assigned  R  groups.  Moieties  highlighted  in  red  differentiate  from  the 
structure of STX;  
¥ ʱ/β epimeric mixture;  
ʦ Relative toxicity based on the mouse bioassay results obtained from [95–98];  
ω Based on binding affinity to human brain, heart and muscle Na
+ channels assessed in Xenopus 
oocytes, respectively [89]. 
A novel group of PSTs with a hydrophobic side chain were identified within the cyanobacterium 
Lyngbya wollei and are characterized by the presence of an acetate at C13 (LWTX 1–3,5,6) and a 
carbinol at C12 (LWTX 2,3,5) in place of a hydrated ketone [82]. This was the first report of STX Mar. Drugs 2010, 8  
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derivatives with a hydrophobic substituent and these toxins have only been found exclusively in the 
freshwater environment [14,82]. The presence of an acetate side chain in the LWTXs correlated with a 
decrease in mouse toxicity, while the reduction at C12 resulted in a complete loss of mouse toxicity [82]. 
Interestingly, Negri et al. reported a novel subclass of analogs containing a hydrophobic R4 side 
chain  designated  GC1-3.  These  were  first  isolated  and  structurally  characterized  from  Australian 
isolates  of  the  dinoflagellate  Gymnodinium  catenatum  and  since  have  also  been  identified  within 
Alexandrium catenatum globally [72]. High-resolution mass-spectrometry (MS) and nuclear magnetic 
resonance spectroscopy (NMR) revealed that GC3 is a 4-hydroxybenzoate ester derivative of dcSTX, 
while  GC1  and  GC2  are  epimeric  11-hydroxysulfate  derivatives  of  GC3  [83,91].  Negri  et  al. 
emphasized  that  the  lipophilic  nature  of  these  toxins  may  lead  to  an  increased  potential  to 
bioaccumulate in marine organisms [72]. These novel analogs have also been shown to bind strongly 
to the voltage gated Na
+ channel. The binding affinity of GC3 resembles the affinity of the GTXs, 
whereas the epimer pair GC1 and GC2 bind with a similar affinity compared to the C-toxins [72,92]. 
More  recently,  other  GC  PST  analogs  have  been  identified,  such  as  GC4-6,  the  di-hydroxylated 
benzoate  GC  analogs  GC1-6a  and  the  sulfated  benzoate  analogs  GC1-6b  for which  only  putative 
structures have been determined via mass spectrometry (MS) [85]. Due to their hydrophobic nature, 
these toxins easily escape conventional chromatography methods. The frequently used C18 solid-phase 
separation  is  based on polarity and  thus  hydrophobic  compounds  are  retained on the column and 
cannot be detected. This is significant from a shellfish monitoring and public safety viewpoint, and 
presents a major challenge to water authorities [72,93,94]. 
Recently,  Vale  et  al.  reported  the  isolation  of  four  unusual  compounds  (denoted  A–D)  and 
categorized them as novel STX analogs based on fluorescence emission, ultraviolet absorption maxima 
and  cross-reactivity  to  a  commercial  antibody  towards  STX  [86].  These  extracts  originated  from 
shellfish  samples  (Semele  proficua  and  Senilia  senilis)  collected  from  Luanda  and  Mussulo  Bay, 
Angola. Compounds A and D were classified as non-N1-hydroxyl PST analogs and compound B as a 
N1-hydroxyl analog. Even though the presence of G. catenatum and Pyrodinium bahamense has been 
reported from the coast of Angola, none of the 18 PSTs commonly found in dinoflagellates were 
identified in these extracts. The authors therefore suggested a possible cyanobacterial source, though 
neither a definitive chemical structure, nor a PST-producing organism were conclusively identified 
[86]. Further analysis of the compounds by MS and NMR is required to elucidate these structures and 
confirm them as STX analogs.  
The  most  exotic  STX  isolate  identified to  date  was isolated  from the Panamanian  golden  frog 
Atelopus zeteki and designated zetekitoxin AB (Tables 1 and 2). Zetekitoxin AB was confirmed to be a 
PST containing a unique 1,2-oxazolidine ring-fused lactam. The binding affinity of zetekitoxin AB for 
brain, heart, and muscle Na
+ channels was extremely potent, displaying a toxicity of approximately 
580-, 160- and 63-fold greater than STX against each channel, respectively [89]. 
The constant discovery of novel and diverse STX analogs is a challenge to PST identification and 
monitoring. Improvement of detection methods will no doubt uncover new natural forms of STX, 
however, we are still only beginning to understand the mechanisms by which these complex molecules 
are produced in nature. Mar. Drugs 2010, 8  
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3. Biotransformation of the Paralytic Shellfish Toxins 
Naturally occurring PSTs may be structurally modified by various biological factors. In some cases, 
these biotransformations can result in new PSTs that cannot be biosynthesized by cyanobacteria or 
dinoflagellates  alone (Figure  2). In  addition, less  toxic PSTs may be converted into analogs with 
greater  toxicity  (e.g.,  C-toxins→GTXs)  or  vice  versa.  Therefore,  a  clearer  understanding  of  PST 
biotransformation is needed for predicting more accurate levels of toxicity. This knowledge may also 
allow for a mechanism of detoxification to be established and utilized in the water supply and shellfish 
farming industries.  
Cell  extracts  of  PST-producing  dinoflagellates  are  capable  of  enzymatically  modifying  PSTs. 
Oshima et al. demonstrated that GTX2 + 3 can be converted into GTX1 + 4 by incubation with 
Alexandrium tamarense homogenate [92]. Introduction of a sulfate moiety on the carbamoyl group, 
resultingin  the  formation  of  C1  and  C2  toxins,  has  been  shown  following  incubation  with 
G. catenatum homogenate [44,99]. In these organisms, biotransformation is likely to occur via inherent 
STX tailoring enzymes which are a part of the SXT biosynthetic pathway encoded within the organism. 
Due to differences in the toxin profiles of filter-feeding invertebrate PST vectors and causative 
producing  organisms,  various  studies  have  been  conducted  to  monitor  toxin  biotransformation 
[84,100–105].  Enzymatic  transformation  of  carbamoyl  and  carbamoyl-N  sulfated  toxins  into  the 
decarbamoyl compounds was detected within the little neck clam,  Prothotheca staminea [106]. In 
addition,  the  conversion  of  the  GTXs  and  neoSTX  to  STX  by  reduction  of  the  O22-sulfate  and  
N1-hydroxyl  groups,  respectively,  has  been  observed  within  the  homogenate  of  the  scallop 
Placopecten magellanicus [107].  
GC1-3 can be converted into dcSTX, as has been confirmed in vitro through incubation of semi-purified 
GC toxins with bivalve digestive glands [93]. Similarly, the recently identified M-toxins (M1-5) are 
reportedly bivalve metabolites of the PSTs and are not present in PST- producing microalgae [56]. The 
M-toxins  constitute  an  important  toxin  fraction  in  mussels  contaminated  by  A. tamarense  and 
G. catenatum and have been detected in shellfish, including mussels, cockles and clams [56,86]. These 
findings are similar to previous reports on the isolation of 11-saxitoxinethanoic acid (SEA), a novel 
PST from the xanthid crab Atergatis floridus, inhabiting the pacific coast of Shikoku Island [87]. Other 
examples  include  a  novel  carbamoyl-N-methylsaxitoxin  (STX-uk)  isolated  from  the  Bangladeshi 
freshwater puffer Tetraodon cutcutia [88]. These exotic STX analogs are likely products of toxin 
transforming  enzymes  within  the vector  organism or  its associated microorganisms. However, the 
mechanism of enzymatic transformation in these organisms is yet to be elucidated [56,86–88,106–109]. 
Biotransformation of the PSTs by bacteria was first suggested many years ago by Kotaki et al., who 
proposed that marine bacteria, such as Vibrio and Pseudomonas spp., are capable of metabolizing 
PSTs [110]. In addition, isolates from the viscera of marine crabs, snails and the marine red algae 
Jania sp., were studied and demonstrated transformation GTX derivatives into STX through reductive 
eliminations [110,111]. Bacterial conversion of GTX1-4 to STX and neoSTX is reportedly due to the 
bacterial thiol compounds glutathione and 2-mercaptoethanol [112]. The ability of bacteria to degrade 
PSTs has been further described by Smith et al., who screened marine bacterial isolates from various 
shellfish species for their ability to metabolize a
 range of PSTs, such as GTX1-5, STX and neoSTX, 
suggesting  that  bacteria  might  play  an  important  role  in  the  clearance  of  PSTs  from  bivalve  Mar. Drugs 2010, 8  
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molluscs [113]. Novel strains of Pseudoalteromonas haloplanktis, isolated from the digestive tracts of 
blue mussels (Mytilus edulis) have been reported to possess the ability to reduce the overall toxicity of 
a PST mixture of algal extracts by 90% within three days [114,115]. Catabolism of the PSTs most 
likely occurred via oxidation reactions catalyzed by oxidases and peroxidases into aliphatic products 
for subsequent use in purine and arginine metabolism, although this is speculated, as no catabolized 
PST  products  could  be  identified  [115].  Degradation  has  also  been  observed  during  the  passage 
through a bioactive treatment plant, leading to a decrease in predominant C-toxins and an increase of 
GTX2 + 3 which display relatively higher toxicity [116]. 
Figure 2. Biotransformation of the paralytic shellfish toxins. Refer to Table 1 for assigned 
R groups. Moieties highlighted in red indicate a differentiation from the structure of STX. 
Unbroken  line  refers  to  experimental  data  of  toxin  conversion.  Broken  line  refers  to 
putative biotransformation based on structural analysis. 
 
GTX1/4
N
N
N
H
N
OH
OH
NH2
+
+H2N
HO
R2 R3
O
H2N
O
GTX2/3
N
N
N
H
N
OH
OH
NH2
+
+H2N
H
R2 R3
O
H2N
O
N
N N
H
N
OH OGluc
NH2
+
+H2N
H
R2 R3
O
H2N
O
GTX2/3-Gluc
C1/2
N
N
N
H
N
OH
OH
NH2
+
+H2N
H
R2 R3
O
N
H
O
-O3S
N
N N
H
N
OH
OH
NH2
+
+H2N
H
HO H
O
O
N
H
-O 3S
M1/3
N
N N
H
N
OH OGluc
NH2
+
+H2N
HO
R2 R3
O
H2N
O
GTX1/4-Gluc
NeoSTX
N
N N
H
N
OH
OH
NH2
+
+H2N
HO
H H
O
H2N
O
dcSTX
N
N
N
H
N
OH
OH
NH2
+
+H2N
H
H H
HO
N
N
N
H
N
OH
OH
NH2
+
+H2N
H
H H
O
H2N
O
STX SEA
N
N N
H
N
OH
OH
NH2
+
+H2N
H
-OOCC
H
O
H2N
O
STX-uk
N
N N
H
N
OH
OH
NH2
+
+H2N
H
H H
O
N
H
O
H3C
N
N N
H
N
OH
OH
NH2
+
+H2N
H
HO R3
O
M2/4
H2N
O
NeoSTX
N
N N
H
N
OH
OH
NH2
+
+H2N
HO
H H
O
H2N
O
dcSTX
N
N N
H
N
OH
OH
NH2
+
+H2N
H
H H
HOMar. Drugs 2010, 8  
 
 
2197 
Detoxification of the paralytic shellfish toxins within mammals 
Metabolism of PSTs by humans has not been studied in depth. Nevertheless, Garcia et al. suggested 
biotransformation of STX to neoSTX and the oxidation of the GTX2 + 3 epimers into GTX1 + 4 
within samples of pancreas, bile, urine, brain and heart obtained post-mortem from PSP victims [26]. 
Further  investigations  confirmed  their  findings  of  biotransformation  in  humans.  N1-oxidation  of 
GTX2 + 3 into the corresponding hydroxylamine analogs GTX1 + 4 has been demonstrated in vitro 
when incubated with a microsomal fraction isolated from healthy human livers. Moreover, in vitro 
glucuronidation of GTX2 + 3 into the hydrophilic compounds GTX3-Gluc and GTX2-Gluc, through 
conjugation at the hydroxyl-C12 group has also been reported (Figure 2) [117]. The oxidation and 
glucuronidation of STX and GTX2 + 3 epimers into neoSTX or GTX1 + 4 epimers, respectively, has 
been suggested to be significant detoxification pathways of GTX2 + 3 and other PSTs in humans and 
other  mammals  [117].  Similar  studies  were  conducted  with  cat  liver,  however,  enzymatic 
transformation  was  not  detected,  with  100%  recovery  of  the  STX  used  in  the  incubation  being 
recovered [118]. This was explained by the fact that with the exception of cats, the liver of mammals 
produces glucuronides as a major metabolic product, thus supporting the specificity of human tissue 
transformation [119]. However, biotransformation of STX was not detected when STX was passaged 
through  rat’s  urine,  indicating  further  mammalian  variability  in  models  [120,121].  Gessner  et  al. 
investigated serum and urine in human PSP victims and detected a significant increase of the PST C1 
in comparison to GTX2, which is distinguished by an additional sulfate on the carbamoyl side group 
[122]. A new assay for STX and neoSTX quantification in human urine samples has been developed 
recently [123]. It is proposed that methodological improvements should also contribute to a better 
understanding of PST profile and its change while passaging through the human body [123].  
The  research  described  above  highlights  the  need  to  characterize  the  diversity  of  biological 
transformations of PSTs. Detoxification pathways could be manipulated to improve biological removal 
strategies, while further characterization of detoxification of PSTs within the human body could lead 
to improved treatment of PSP. 
4. A Genetic Basis for the Paralytic Shellfish Toxins 
4.1. The saxitoxin biosynthetic gene cluster 
Recently  the saxitoxin biosynthesis pathway was proposed [124], and the sxt gene cluster  was 
identified in three cyanobacterial species of the family Nostocaceae [33,34] and one from the family 
Oscillatoriaceae [125]. The sxt gene clusters within each organism all contain a core set of genes 
putatively responsible for the biosynthesis of STX. However, the gene profile between each cluster 
differs,  resulting  in  the  production  of  a  different  suite  of  STX  analogs  by  each  organism.  It  is 
foreseeable that identification of the cyanobacterial PST biosynthesis genes will eventually lead to the 
identification of the homologs within dinoflagellates. However, the dinoflagellate PST biosynthesis 
genes remain elusive. There is also some debate on whether the enzymes for PST biosynthesis are 
encoded by the dinoflagellate genome, including plastids or other sources such as symbiotic bacteria or 
viruses [126–128]. Mar. Drugs 2010, 8  
 
 
2198 
In cyanobacteria, biosynthesis of STX is catalyzed by several enzymes otherwise rare in microbial 
metabolism.  The  core  PST  biosynthetic  gene,  sxtA,  is  thought  to  have  a  chimeric  origin  and  is 
putatively responsible for the initiation of STX biosynthesis, catalysing the incorporation of acetate to 
the  enzyme  complex  and  its  subsequent  methylation  and  Claisen  condensation  with  arginine 
[33,34,129].  SxtA  consists  of  four  catalytic  domains  (SxtA1-SxtA4)  with  the  N-terminal  region 
showing  similarities  to  a  polyketide  synthase  (PKS)  complex  [130]  consisting  of  a  GCN5-related  
N-acetyltransferase [131], acyl-carrier protein (ACP) and a S-adenosylmethionine-dependant (SAM) 
methyltransferase  [132]  domains,  while  the  C-terminal  region  contains  a  domain  homologous  to 
previously characterized aminotransferases [133].  
Specific PST analog profiles are proposed to be the result of tailoring enzymes encoded by the sxt 
gene cluster. The function of tailoring enzymes within each of the characterized sxt clusters has been 
inferred  by analysis of the specific  toxin profile  produced  by each  cyanobacterium. For example, 
neoSTX differs from STX by hydroxylation at the N1 position (Table 1). NeoSTX is produced by 
C. raciborskii T3, Aphanizomenon sp. NH-5 and L. wollei, but has not been detected in A. circinalis 
[14,35,36,57,62]. Sequence analysis of the four sxt gene clusters revealed SxtX as a protein putatively 
responsible  for  the  N1-hydroxylation  of  STX,  since  sxtX  was  identified  in  all  neoSTX  producing 
strains and absent from the A. circinalis AWQC131C gene cluster [33,34]. This protein displayed high 
structural  similarities  to  cephalosporin  hydroxylase  [134],  further  affirming  its  role  in  the  
N1-hydroxylation of STX.  
The GTXs are produced by mono-sulfation at N21 or O22 of STX which can then be di-sulfated to 
produce  the  C-toxins.  Previous  studies  of  the  dinoflagellate  G.  catenatum,  revealed  two  
3′-phosphate 5′-phosphosulfate (PAPS)-dependant sulfotransferases responsible for the N21 sulfation 
of STX, GTX2 and GTX3, and the O22 sulfation of 11-hydroxy STX [135,136]. Two genes, sxtO, a 
PAPS forming enzyme and sxtN, a sulfotransferase, within cyanobacterial sxt clusters are proposed to 
encode proteins that play a similar sulfation role in the synthesis of GTXs and C-toxins. 
The requirement of SAM for STX biosynthesis has long been hypothesized and thus has been 
targeted during attempts to identify the PST genes [137,138]. Harlow et al. were able to use degenerate 
primers to screen several dinoflagellate genomes in an attempt to identify genes encoding SAM as a 
candidate  involved  in  PST  biosynthesis  [138].  Although  several  SAM  genes  were  successfully 
identified  within  dinoflagellates,  these  were  not  correlated  to  PST  biosynthesis.  The  study  was 
hampered  by  a  limited  knowledge  of  dinoflagellate  codon  usage  and  a  lack  of  related  sequence 
information  within  the  NCBI  database  [138,139].  Kellmann  et  al. used  a  similar degenerate  PCR 
approach to identify a gene encoding a O-carbamoyltransferase (sxtI), which ultimately led to the 
identification of the entire sxt biosynthesis pathway in cyanobacteria [33,138,140]. There are now 
multiple genes that may be utilized to target homologs of the sxt cluster in dinoflagellates. However, a 
recent study identified the dinoflagellate sxt cluster may differ from cyanobacteria more than would be 
expected from a recent gene transfer event. Hence, mRNA present solely within toxic dinoflagellates 
may be more successful at identifying the candidate sxt pathway in these organisms [141]. Mar. Drugs 2010, 8  
 
 
2199 
4.2. Pharmaceutical potential of the paralytic shellfish toxins 
Recent years has seen a renewed interest in marine alkaloids and their analogs, including the PSTs, 
with regards to their use as therapeutic agents or as a drug lead. Bioactivity studies and molecular 
modeling  of  a  range  of  PSTs  could  also  lead  to  the  design  of  unnatural  analogs  with  improved 
pharmaceutical characteristics. Recently, a group of toxins isolated from marine cone snails (genus 
Conus), known as conotoxins, have been shown to contain over 2,000 peptide analogs [142]. The 
conotoxins are able to specifically target a broad range of ion channels and membrane receptors with 
several currently under investigation for possible clinical trials [142]. In 2004, a synthetic version of a 
single conotoxin analog, ω-conotoxin MVIIA, also known as ziconotide (trade name Prialt
®) was the 
first marine natural product to be approved for use by the US Food and Drug Administration since 
1976 [143,144]. Ziconotide acts by targeting N-type voltage sensitive Ca
2+ channels and is used for the 
treatment of chronic pain in spinal cord injury [145,146].  
Like  Prialt
®, STX also  has  a  huge  pharmaceutical potential for its  ability  to  induce anesthesia 
through interaction with site 1 of the voltage gated Na
+ channel [38,39]. It has been suggested that site 
1 blockers prolong the duration of anaesthesia in a synergistic manner when combined with other local 
anaesthetics [39,147,148]. In spite of this, the push for STX to enter clinical trials has been hindered 
by its systematic toxicity [149]. The use of STX as a slow release, prolonged anesthetic was recently 
demonstrated using a novel controlled release system in male Sprague-Dawley rats [150]. Liposomal 
formulations of STX, either alone and in conjunction with dexamethasone and/or bupivacaine, were 
able to block the sciatic nerve within rats for long periods with no damaging myotoxic, cytotoxic or 
neurotoxic effects and little associated inflammation [150]. Liposome formulations of STX for slow 
and site-directed release for prolonged anaesthesia have since been postulated as a putative treatment 
of localized pain and severe joint pain [151]. 
PSTs such as GTX2 + 3 also have clinical potential and have been utilized for the treatment of anal 
fissures [152–154]. Since 1951, surgery has been the most common form of anal fissure treatment with 
several possible side effects [155–157], while other treatments include ointments [158], botulinium 
toxin [159] and topical application of nitroglycerine [160]. Treatment with GTX2 + 3 involves direct 
injection into both sides of the fissure. A success rate of 98% with remission after 15 and 28 days for 
acute and chronic conditions, respectively (n = 100) was observed [153]. A follow up study with an 
enhanced method has since been performed by Garrido et al. with an improved time of healing of 
seven to 14 days for chronic cases (n = 23) [154]. Both studies identified GTX2 + 3 as safe and 
effective  when  compared  to  other  treatments  [153,154].  GTX2  +  3  have  also  been  used  in  the 
treatment of chronic tension type headache, with 70% of patients (n = 27) responding to treatment 
[161]. These studies recognize that PSTs other than STX also have potential as future pharmaceutical 
leads. Their use in the past has also been limited largely due to problems obtaining purified PST analogs. 
The genetic characterization of PST biosynthesis pathways from diverse producer organisms has 
increased our insight into sxt tailoring reactions and the molecular understanding of the mechanisms 
by which a particular suite of PSTs can be synthesized. This will ultimately advance research into the 
pharmaceutical  potential  of  the  PSTs  as  Na
+  channel  blockers,  by  generating  new  analogs  or  by 
increasing the availability of analogs otherwise biosynthesized in low concentrations. Bioengineering 
can also be utilized to further enhance the structural diversity of bioactive small molecules by using Mar. Drugs 2010, 8  
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in vitro approaches that utilize enzymes in chemical synthesis, as well as in vivo approaches, such as 
combinatorial biosynthesis [40,41]. Combinatorial biosynthesis is the process of incorporating genes 
from multiple biosynthetic clusters into an expression plasmid, in a combinatorial fashion, to generate 
a  library  of  ―unnatural‖  natural  products  expressed  in  vivo.  However  expression  of  large  gene 
fragments in a heterologous host is required and analogs of interest may then be extracted, purified and 
assayed to determine their bioactivity.  
The bioactive nature of STX as an anaesthetic and GTX2 + 3 for the treatment of anal fissures and 
chronic  tension  type  headaches  demonstrates  that  these  alkaloids  have  pharmaceutical  potential 
deserving of further investigation. The recent elucidation of the sxt gene clusters in cyanobacteria and 
the identification of novel PSTs has provided more options for further PST bioactivity studies. Novel 
analogs could also be devised by redesigning PST biosynthesis genes in amenable host systems via 
combinatorial biosynthesis.  
5. Conclusions 
The structure of STX has been known for 53 years and the discovery of novel STX analogs has 
continued  steadily  ever  since.  Today,  57  PST  analogs  have  been  reported.  With  more  sensitive 
detection methods, new STX analogs will most likely continue to be identified, with new functional 
moieties and possibly novel bioactivity. Despite extended research on the role of saxitoxin and its 
analogs as a sodium channel blocker, the effect of these toxins on the environment, and the genes that 
are responsible for their production, there is still a vast gap in knowledge in regards to their potential 
intracellular role within the producing organism. Nevertheless, it is possible that the different analogs 
display varying functions within the cells due to their partial differences in charges and chemical 
properties. More studies are needed to elucidate the localization of saxitoxin and its derivatives might 
provide clues to the potential role of the PST analogs within the producing organism. In the future, a 
better understanding of the intracellular and extracellular functions of STX might open more avenues 
for pharmaceutical applications. 
Since  PSTs  are  produced  by  distantly  related  organisms,  spanning  two  domains,  including 
cyanobacteria, dinoflagellates and the Panamanian golden frog, it is possible that their occurrence in 
nature is more widespread than we know. Further investigations are needed to elucidate the extent of 
their distribution, diversity and their fundamental biology, such as their biosynthesis, metabolic and 
eco-physiological function. This is in addition to the role of chemical transformation of the different 
toxins in shellfish and the environment.  
Future research is also needed to understand the integration of PST biosynthesis within the overall 
cell metabolism and the possible recruitment of enzymes from other biosynthetic pathways for PST 
bioconversions.  Proteomic  and  transcriptomic  studies  are  likely  to  provide  a  link  between  STX 
biosynthesis, regulation and cellular metabolism. It is expected that data will allow us to acquire a 
better understanding of the conservation of the SXT biosynthesis pathway at the enzymatic level in 
comparison to the genetic level, may give further insight into the molecular function of these toxins 
and also lead to clues of their evolutionary history. In future, characterization of PST biosynthetic 
genes  from  dinoflagellates  and  comparison  with  cyanobacterial  genes  will  also  aid  in  our 
understanding of the evolutionary history of these genes with regard to their origin and transfer.  Mar. Drugs 2010, 8  
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PSP is a serious health problem and its incidence has continued to rise on a global scale. PSTs 
negatively  impact  the  fisheries  industry  globally  and  the  development  of  novel  methods  of 
detoxification is essential from a human health and financial perspective [104,113,162]. The enzymatic 
basis for the structural diversity of PSTs is now beginning to be understood from the genetics of their 
biosynthesis in cyanobacteria and characterization of transformations catalyzed by bacteria, marine 
invertebrates  and  mammals.  Biotransformation  pathways  could  also  be  manipulated  to  efficiently 
remove toxins from water supplies. Specific enzymes or bacterial strains that degrade PSTs could be 
introduced into shellfish to assist detoxification. Currently, the PSTs represent extraordinary potential 
for  pharmacy.  This  potential  is  likely  to  increase  as  we  continue  to  gain  a  better  molecular 
understanding of the PSTs, leading to future prospects of their use in combinatorial biosynthesis for 
the production of novel alkaloids with beneficial application. 
Acknowledgements 
The authors would like to thank the Australian Research Council, Diagnostic Technology, NSW 
Department  of  Primary  Industries,  Safe  Food  NSW,  Department  of  Health  and  Human  Services 
Tasmania and Primary Industries and Resources SA for supporting this work. 
References  
1.  Schantz, E.J.; Mold, J.; Stanger, D.; Shavel, J.; Riel, F.; Bowden, J.; Lynch, J.; Wyler, R.; Riegel, 
B.; Sommer, H. Paralytic shellfish poison VI. A procedure for the isolation and purification of 
the poison from toxic clams and mussel tissues. J. Am. Chem. Soc. 1957, 79, 5230–5235. 
2.  Anderson, D.M.; Cembella, A.D.; Hallegraeff, G.M. Physiological Ecology of Harmful Algal 
Blooms, 1st ed.; Springer: Berlin, Germany, 1998; p. 662. 
3.  Anderson,  D.M.;  Glibert,  P.M.;  Burkholder,  J.M.  Harmful  algal  blooms  and  eutrophication: 
Nutrient sources, composition, and consequences. Estuaries 2002, 25, 704–726. 
4.  Sellner,  K.G.;  Doucette,  G.J.;  Kirkpatrick,  G.J.  Harmful  algal  blooms:  Causes,  impacts  and 
detection. J. Ind. Microbiol. Biotechnol. 2003, 30, 383–406. 
5.  Zingone, A.; Enevoldsen, H.O. The diversity of harmful algal blooms: A challenge for science 
and management. Ocean Coast. Manage. 2000, 43, 725–748. 
6.  Van Dolah, F.M. Marine algal toxins: Origins, health effects, and their increased occurrence. 
Environ. Health Perspect. 2000, 108, 133–141. 
7.  Llewellyn, L.E. Saxitoxin, a toxic marine natural product that targets a multitude of receptors. 
Nat. Prod. Rep. 2006, 23, 200–222. 
8.  Lefebvre, K.A.; Bill, B.D.; Erickson, A.; Baugh, K.A.; O'Rourke, L.; Costa, P.R.; Nance, S.; 
Trainer, V.L. Characterization of intracellular and extracellular saxitoxin levels in both field and 
cultured  Alexandrium  spp.  samples  from  Sequim  Bay,  Washington.  Mar.  Drugs  2008,  6,  
103–116. 
9.  Oshima, Y.; Blackburn, S.I.; Hallegraeff, G.M. Comparative study on paralytic shellfish toxin 
profiles of the dinoflagellate Gymnodinium catenatum from three different countries. Mar. Biol. 
1993, 116, 471–476. Mar. Drugs 2010, 8  
 
 
2202 
10.  Usup, G.; Kulis, D.M.; Anderson, D.M. Growth and toxin production of the toxic dinoflagellate 
Pyrodinium bahamense var. compressum in laboratory cultures. Nat. Toxins 1994, 2, 254–262. 
11.  Gainey, L.; Shumway, J.; Shumway, S. A compendium of the responses of bivalve molluscs to 
toxic dinoflagellates. J. Shellfish Res. 1988, 7, 623–628. 
12.  Shumway, S.E. Phycotoxin-related shellfish poisoning: Bivalve molluscs are not the only vectors 
Rev. Fish. Sci. 1995, 3, 1–31. 
13.  Deeds,  J.;  Landsberg,  J.;  Etheridge,  S.;  Pitcher,  G.;  Longan,  S.  Non-traditional  vectors  for 
paralytic shellfish poisoning. Mar. Drugs 2008, 6, 308–348. 
14.  Carmichael, W.W.; Evans, W.R.; Yin, Q.Q.; Bell, P.; Moczydlowski, E. Evidence for paralytic 
shellfish poisons in the freshwater cyanobacterium Lyngbya wollei (Farlow ex Gomont) comb. 
nov. Appl. Environ. Microbiol. 1997, 63, 3104–3110. 
15.  Hoeger,  S.J.;  Shaw,  G.;  Hitzfeld,  B.C.;  Dietrich,  D.R.  Occurrence  and  elimination  of 
cyanobacterial  toxins  in  two  Australian  drinking  water  treatment  plants.  Toxicon  2004,  43,  
639–649. 
16.  Molica, R.J.R.; Oliveira, E.J.A.; Carvalho, P.V.V.C.; Costa, A.N.S.F.; Cunha, M.C.C.; Melo, 
G.L.; Azevedo, S.M.F.O. Occurrence of saxitoxins and an anatoxin-a(s)-like anticholinesterase 
in a Brazilian drinking water supply. Harmful Algae 2005, 4, 743–753. 
17.  Clemente, Z.; Busato, R.H.; Oliveira Ribeiro, C.A.; Cestari, M.M.; Ramsdorf, W.A.; Magalhã es, 
V.F.; Wosiack, A.C.; Silva de Assis, H.C. Analyses of paralytic shellfish toxins and biomarkers 
in a southern Brazilian reservoir. Toxicon 2010, 55, 396–406. 
18.  Liu, Y.; Chen, W.; Li, D.; Shen, Y.; Li, G.; Liu, Y. First report of aphantoxins in China—
waterblooms of toxigenic Aphanizomenon flos-aquae in Lake Dianchi. Ecotoxicol. Environ. Saf. 
2006, 65, 84–92. 
19.  Berry, J.P.; Lind, O. First evidence of "paralytic shellfish toxins" and cylindrospermopsin in a 
Mexican  freshwater  system,  Lago  Catemaco,  and  apparent  bioaccumulation  of  the  toxins  in 
"tegogolo" snails (Pomacea patula catemacensis). Toxicon 2010, 55, 930–938. 
20.  Ballot, A.; Fastner, J.; Wiedner, C. Paralytic shellfish poisoning toxin-producing cyanobacterium 
Aphanizomenon gracile in Northeast Germany. Appl. Environ. Microbiol. 2010, 76, 1173–1180. 
21.  Codd, G.A. Cyanobacterial toxins: occurrence, properties and biological significance. Water Sci. 
Technol. 1995, 32, 149–156. 
22.  Sivonen, K.; Jones, G. Cyanobacterial toxins. In  Toxin Cyanobacteria in Water: A Guide to 
Their Public Health Consequences, Monitoring and Management; Chorus, I., Bartram, J., Eds.; 
WHO E & FN Spon: London, UK, 1999; pp. 41–111. 
23.  Kao,  C.Y.  Paralytic  shellfish  poisoning.  In  Algal  Toxins  in  Seafood  and  Drinking  Water; 
Falconer, E.R., Ed.; Academic: London, UK, 1993; p. 75. 
24.  Anderson, D.M.; Kulis, D.M.; Qi, Y.; Zheng, L.; Lu, S.; Lin, Y. Paralytic shellfish poisoning in 
Southern China. Toxicon 1996, 34, 579–590. 
25.  Rodrigue, D.C.; Etzel, R.A.; Hall, S.; de Porras, E.; Velasquez, O.H.; Tauxe, R.V.; Kilbourne, 
E.M.; Blake, P.A. Lethal paralytic shellfish poisoning in Guatemala. Am. J. Trop. Med. Hyg. 
1990, 42, 267–271. Mar. Drugs 2010, 8  
 
 
2203 
26.  Garcia,  C.;  del  Carmen  Bravo,  M.;  Lagos,  M.;  Lagos,  N.  Paralytic  shellfish  poisoning:  
Post-mortem analysis of tissue and body fluid samples from human victims in the Patagonia 
fjords. Toxicon 2004, 43, 149–158. 
27.  Landsberg,  J.H.;  Hall,  S.;  Johannessen,  J.N.;  White,  K.D.;  Conrad,  S.M.;  Abbott,  J.P.; 
Flewelling, L.J.; Richardson, R.W.; Dickey, R.W.; Jester, E.L.; Etheridge, S.M.; Deeds, J.R.; 
Van Dolah, F.M.; Leighfield, T.A.; Zou, Y.; Beaudry, C.G.; Benner, R.A.; Rogers, P.L.; Scott, 
P.S.; Kawabata, K.; Wolny, J.L.; Steidinger, K.A. Saxitoxin puffer fish poisoning in the United 
States, with the first report of Pyrodinium bahamense as the putative toxin source. Environ. 
Health Perspect. 2006, 114, 1502–1507. 
28.  Catterall, W.A.; Morrow, C.S.; Hartshorne, R.P. Neurotoxin binding to receptor sites associated 
with  voltage-sensitive  sodium  channels  in  intact,  lysed,  and  detergent-solubilized  brain 
membranes. J. Biol. Chem. 1979, 254, 11379–11387. 
29.  Catterall,  W.A.  Neurotoxins  that  act  on  voltage-sensitive  sodium  channels  in  excitable 
membranes. Annu. Rev. Pharmacol. 1980, 20, 15–43. 
30.  Cestè le, S.; Catterall, W.A. Molecular mechanisms of neurotoxin action on voltage-gated sodium 
channels. Biochimie 2000, 82, 883–892. 
31.  Guy,  A.L.;  Griffin,  G.  Adopting  alternatives  for  the  regulatory  monitoring  of  shellfish  for 
paralytic shellfish poisoning in Canada: Interface between federal regulators, science and ethics. 
Regul. Toxicol. Pharmacol. 2009, 54, 256–263. 
32.  Stewart, I.; Seawright, A.A.; Shaw, G.R. Cyanobacterial poisoning in livestock, wild mammals 
and birds—an overview. In Cyanobacterial Harmful Algal Blooms: State of the Science and 
Research Needs; Hudnell, H.K., Ed.; Springer: New York, NY, USA, 2008; pp. 613–637. 
33.  Kellmann,  R.;  Mihali,  T.K.;  Jeon,  Y.J.;  Pickford,  R.;  Pomati,  F.;  Neilan,  B.A.  Biosynthetic 
intermediate analysis and functional homology reveal a saxitoxin gene cluster in cyanobacteria. 
Appl. Environ. Microbiol. 2008, 74, 4044–4053. 
34.  Mihali,  T.K.;  Kellmann,  R.;  Neilan,  B.A.  Characterisation  of  the  paralytic  shellfish  toxin 
biosynthesis gene clusters in Anabaena circinalis AWQC131C and Aphanizomenon sp. NH-5. 
BMC Biochem. 2009, 10, 8. 
35.  Llewellyn, L.E.; Negri, A.P.; Doyle, J.; Baker, P.D.; Beltran, E.C.; Neilan, B.A. Radioreceptor 
assays for sensitive detection and quantitation of saxitoxin and its analogues from strains of the 
freshwater cyanobacterium, Anabaena circinalis. Environ. Sci. Technol. 2001, 35, 1445–1451. 
36.  Lagos, N.; Onodera, H.; Zagatto, P.A.; Andrinolo, D.; Azevedo, S.M.F.Q.; Oshima, Y. The first 
evidence  of  paralytic  shellfish  toxins  in  the  freshwater  cyanobacterium  Cylindrospermopsis 
raciborskii, isolated from Brazil. Toxicon 1999, 37, 1359–1373. 
37.  Ferreira,  F.M.B.;  Soler,  J.M.F.;  Fidalgo,  M.L.;  Ferná ndez-Vila,  P.  PSP  toxins  from 
Aphanizomenon  flos-aquae (cyanobacteria)  collected  in  the Crestuma-Lever reservoir (Douro 
river, northern Portugal). Toxicon 2001, 39, 757–761. 
38.  Hille, B. The receptor for tetrodotoxin and saxitoxin. A structural hypothesis. Biophys. J. 1975, 
15, 615–619. 
39.  Adams, H.J.; Blair, M.R., Jr.; Takman, B.H. The local anesthetic activity of saxitoxin alone and 
with  vasoconstrictor  and  local  anesthetic  agents.  Arch.  Int.  Pharmacodyn.  Ther.  1976,  224,  
275–282. Mar. Drugs 2010, 8  
 
 
2204 
40.  Khosla, C.; Keasling, J.D. Metabolic engineering for drug discovery and development. Nat. Rev. 
Drug Discov. 2003, 2, 1019–1025. 
41.  Zhang, W.; Tang, Y. Combinatorial biosynthesis of natural products. J. Med. Chem. 2008, 51, 
2629–2633. 
42.  Bordner, J.; Thiessen, W.E.; Bates, H.A.; Rapoport, H. Structure of a crystalline derivative of 
saxitoxin. Structure of saxitoxin. J. Am. Chem. Soc. 1975, 97, 6008–6012. 
43.  Schantz, E.J.; Ghazarossian, V.E.; Schnoes, H.K.; Strong, F.M.; Springer, J.P.; Pezzanite, J.O.; 
Clardy, J. Structure of saxitoxin. J. Am. Chem. Soc. 1975, 97, 1238–1239. 
44.  Shimizu,  Y.  Chemistry  and  mechanism  of  action.  In  Seafood  and  Freshwater  Toxins: 
Pharmacology, Physiology, and Detection; Botana, L.M., Ed.; Marcel Dekker: New York, NY, 
USA, 2000; pp. 151–172. 
45.  Berlinck,  R.G.S.;  Kossuga,  M.H.  Natural  guanidine  derivatives.  Nat.  Prod.  Rep.  2005,  22,  
516–550. 
46.  Ciminiello, P.; Fattorusso, E.; Forino, M.; Montresor, M. Saxitoxin and neosaxitoxin as toxic 
principles  of  Alexandrium  andersoni  (Dinophyceae)  from  the  Gulf  of  Naples,  Italy.  Toxicon 
2000, 38, 1871–1877. 
47.  Siu, G.; Young, M.; Chan, D. Environmental and nutritional factors which regulate population 
dynamics and toxin production in the dinoflagellate Alexandrium catenella. Hydrobiologia 1997, 
352, 117–140. 
48.  Sebastiá n, C.R.; Etheridge, S.M.; Cook, P.A.; O'Ryan, C.; Pitcher, G.C. Phylogenetic analysis of 
toxic  Alexandrium  (Dinophyceae)  isolates  from  South  Africa:  implications  for  the  global 
phylogeography of the Alexandrium tamarense species complex. Phycologia 2005, 44, 49–60. 
49.  Krock,  B.;  Seguel,  C.G.;  Cembella,  A.D.  Toxin  profile  of  Alexandrium  catenella  from  the 
Chilean coast as determined by liquid chromatography with fluorescence detection and liquid 
chromatography coupled with tandem mass spectrometry. Harmful Algae 2007, 6, 734–744. 
50.  Poulton,  N.J.;  Keafer,  B.A.;  Anderson,  D.M.  Toxin  variability  in  natural  populations  of 
Alexandrium fundyense in Casco Bay, Maine—evidence of nitrogen limitation. Deep-Sea Res. 
PT. II 2005, 52, 2501–2521. 
51.  Anderson, D.M.; Kulis, D.M.; Sullivan, J.J.; Hall, S. Toxin composition variations in one isolate 
of the dinoflagellate Alexandrium fundyense. Toxicon 1990, 28, 885–893. 
52.  Jaime, E.; Gerdts, G.; Luckas, B. In vitro transformation of PSP toxins by different shellfish 
tissues. Harmful Algae 2007, 6, 308–316. 
53.  Parkhill,  J.;  Cembella,  A.  Effects  of  salinity,  light  and  inorganic  nitrogen  on  growth  and 
toxigenicity  of  the  marine  dinoflagellate  Alexandrium  tamarense  from  northeastern  Canada.  
J. Plankton Res. 1999, 21, 939–955. 
54.  Yu, R.; Hummert, C.; Luckas, B.; Qian, P.; Li, J.; Zhou, M. A modified HPLC method for 
analysis of PSP toxins in algae and shellfish from china. Chromatographia 1998, 48, 671–676. 
55.  Ichimi,  K.;  Suzuki,  T.;  Ito,  A.  Variety  of  PSP  toxin  profiles  in  various  culture  strains  of 
Alexandrium tamarense and change of toxin profile in natural A. tamarense population. J. Exp. 
Mar. Biol. Ecol. 2002, 273, 51–60. Mar. Drugs 2010, 8  
 
 
2205 
56.  Dell'Aversano,  C.;  Walter,  J.A.;  Burton,  I.W.;  Stirling,  D.J.;  Fattorusso,  E.;  Quilliam,  M.A. 
Isolation and structure elucidation of new and unusual saxitoxin analogues from mussels. J. Nat. 
Prod. 2008, 71, 1518–1523. 
57.  Velzeboer,  R.M.A.;  Baker,  P.D.;  Rositano,  J.;  Heresztyn,  T.;  Codd,  G.A.;  Raggett,  S.L. 
Geographical patterns of occurrence and composition of saxitoxins in the cyanobacterial genus 
Anabaena (Nostocales, Cyanophyta) in Australia. Phycologia 2000, 39, 395–407. 
58.  Testé , V.; Briand, J.-F.; Nicholson, B.C.; Puiseux-Dao, S. Comparison of changes in toxicity 
during  growth  of  Anabaena  circinalis  (cyanobacteria)  determined  by  mouse  neuroblastoma 
bioassay and HPLC. J. Appl. Phycol. 2002, 14, 399–407. 
59.  Negri, A.P.; Jones, G.J. Bioaccumulation of paralytic shellfish poisoning (PSP) toxins from the 
cyanobacterium Anabaena circinalis by the freshwater mussel Alathyria condola. Toxicon 1995, 
33, 667–678. 
60.  Dias, E.; Pereira, P.; Franca, S. Production of the paralytic shellfish toxins by Aphanizomenon sp. 
LMECYA 31 (cyanobacteria). J. Phycol. 2002, 38, 705–712. 
61.  Ikawa, M.; Wegener, K.; Foxall, T.L.; Sasner, J.J., Jr. Comparison of the toxins of the blue-green 
alga Aphanizomenon flos-aquae with the Gonyaulax toxins. Toxicon 1982, 20, 747–752. 
62.  Mahmood,  N.A.;  Carmichael,  W.W.  Paralytic  shellfish  poisons  produced  by  the  freshwater 
cyanobacterium Aphanizomenon flos-aquae NH-5. Toxicon 1986, 24, 175–186. 
63.  Pereira, P.; Onodera, H.; Andrinolo, D.; Franca, S.; Araú jo, F.; Lagos, N.; Oshima, Y. Paralytic 
shellfish  toxins  in  the  freshwater  cyanobacterium  Aphanizomenon  flos-aquae,  isolated  from 
Montargil reservoir, Portugal. Toxicon 2000, 38, 1689–1702. 
64.  Pereira, P.; Li, R.; Carmichael, W.; Dias, E.; Franca, S. Taxonomy and production of paralytic 
shellfish toxins by the freshwater cyanobacterium Aphanizomenon gracile LMECYA40. Eur. J. 
Phycol. 2004, 39, 361–368. 
65.  Nogueira, I.C.G.; Pereira, P.; Dias, E.; Pflugmacher, S.; Wiegand, C.; Franca, S.; Vasconcelos, 
V.M. Accumulation of paralytic shellfish toxins (PST) from the cyanobacterium Aphanizomenon 
issatschenkoi by the cladoceran Daphnia magna. Toxicon 2004, 44, 773–780. 
66.  Rapala, J.; Robertson, A.; Negri, A.P.; Berg, K.A.; Tuomi, P.; Lyra, C.; Erkomaa, K.; Lahti, K.; 
Hoppu, K.; Lepistö , L. First report of saxitoxin in Finnish lakes and possible associated effects 
on human health. Environ. Toxicol. 2005, 20, 331–340. 
67.  Castro, D.; Vera, D.; Lagos, N.; Garcí a, C.; Vá squez, M. The effect of temperature on growth 
and  production  of  paralytic  shellfish  poisoning  toxins  by  the  cyanobacterium 
Cylindrospermopsis raciborskii C10. Toxicon 2004, 44, 483–489. 
68.  Pomati, F.; Moffitt, M.C.; Cavaliere, R.; Neilan, B.A. Evidence for differences in the metabolism 
of saxitoxin and C1+2 toxins in the freshwater cyanobacterium Cylindrospermopsis raciborskii 
T3. BBA-Gen. Subjects 2004, 1674, 60–67. 
69.  Molica, R.; Onodbra, H.; Garcia, C.; Rivas, M.; Andrinolo, D.; Nascimento, S.; Meguro, H.; 
Oshimo,  Y.;  Azevedo,  S.;  Lagos,  N.  Toxins  in  the  freshwater  cyanobacterium 
Cylindrospermopsis  raciborskii  (Cyanophyceae)  isolated  from  Tabocas  reservoir  in  Caruaru, 
Brazil, including demonstration of a new saxitoxin analogue. Phycologia 2002, 41, 606–611. Mar. Drugs 2010, 8  
 
 
2206 
70.  Holmes, M.J.; Bolch, C.J.S.; Green, D.H.; Cembella, A.D.; Teo, S.L.M. Singapore isolates of the 
dinoflagellate  Gymnodinium  catenatum  (Dinophyceae)  produce  a  unique  profile  of  paralytic 
shellfish poisoning toxins. J. Phycol. 2002, 38, 96–106. 
71.  Gá rate-Lizá rraga,  I.;  Bustillos-Guzmá n,  J.J.;  Morquecho,  L.;  Band-Schmidt,  C.J.;  Alonso-
Rodrí guez, R.; Erler, K.; Luckas, B.; Reyes-Salinas, A.; Gó ngora-Gonzá lez, D.T. Comparative 
paralytic shellfish toxin profiles in the strains of Gymnodinium catenatum Graham from the Gulf 
of California, Mexico. Mar. Pollut. Bull. 2005, 50, 211–217. 
72.  Negri,  A.P.;  Bolch,  C.J.S.;  Geier,  S.;  Green,  D.H.;  Park,  T.-G.;  Blackburn,  S.I.  Widespread 
presence of hydrophobic paralytic shellfish toxins in Gymnodinium catenatum. Harmful Algae 
2007, 6, 774–780. 
73.  Pomati, F.; Sacchi, S.; Rossetti, C.; Giovannardi, S.; Onodera, H.; Oshima, Y.; Neilan, B.A. The 
freshwater  cyanobacterium  Planktothrix  sp.  FP1:  Molecular  identification  and  detection  of 
paralytic shellfish poisoning toxins. J. Phycol. 2000, 36, 553–562. 
74.  Liu, Y.; Chen, W.; Li, D.; Shen, Y.; Liu, Y.; Song, L. Analysis of paralytic shellfish toxins in 
Aphanizomenon DC-1 from Lake Dianchi, China. Environ. Toxicol. 2006, 21, 289–295. 
75.  Navarro, J.M.; Muñ oz, M.G.; Contreras, A.M. Temperature as a factor regulating growth and 
toxin content in the dinoflagellate Alexandrium catenella. Harmful Algae 2006, 5, 762–769. 
76.  Samsur, M.; Yamaguchi, Y.; Sagara, T.; Takatani, T.; Arakawa, O.; Noguchi, T. Accumulation 
and depuration profiles of PSP toxins in the short-necked clam Tapes japonica fed with the toxic 
dinoflagellate Alexandrium catenella. Toxicon 2006, 48, 323–330. 
77.  Franco,  J.;  Ferná ndez,  P.;  Reguera,  B.  Toxin  profiles  of  natural  populations  and  cultures  of 
Alexandrium minutum Halim from Galician (Spain) coastal waters. J. Appl. Phycol. 1994, 6, 
275–279. 
78.  Hwang, D.-F.; Lu, Y.-H.; Noguchi, T. Effects of exogenous polyamines on growth, toxicity, and 
toxin profile of dinoflagellate Alexandrium minutum. J. Food Hyg. Soc. Jpn. 2003, 44, 49–53. 
79.  Pitcher, G.C.; Cembella, A.D.; Joyce, L.B.; Larsen, J.; Probyn, T.A.; Ruiz Sebastiá n, C. The 
dinoflagellate  Alexandrium  minutum  in  Cape  Town  harbour  (South  Africa):  Bloom 
characteristics, phylogenetic analysis and toxin composition. Harmful Algae 2007, 6, 823–836. 
80.  Hansen, P.J.; Cembella, A.D.; Moestrup, Ø. The marine dinoflagellate Alexandrium ostenfeldii: 
Paralytic shellfish toxin concentration, composition and toxicity to a tintinnid cilliate. J. Phycol. 
1992, 28, 597–603. 
81.  Vale,  P.  Metabolites  of  saxitoxin  analogues  in  bivalves  contaminated  by  Gymnodinium 
catenatum. Toxicon 2010, 55, 162–165. 
82.  Onodera,  H.;  Satake,  M.;  Oshima,  Y.;  Yasumoto,  T.;  Carmichael,  W.W.  New  saxitoxin 
analogues from the freshwater filamentous cyanobacterium Lyngbya wollei. Nat. Toxins 1997, 5, 
146–151. 
83.  Negri,  A.;  Stirling,  D.;  Quilliam,  M.;  Blackburn,  S.;  Bolch,  C.;  Burton,  I.;  Eaglesham,  G.; 
Thomas, K.; Walter, J.; Willis, R. Three novel hydroxybenzoate saxitoxin analogues isolated 
from the dinoflagellate Gymnodinium catenatum. Chem. Res. Toxicol. 2003, 16, 1029–1033. 
84.  Oshima, Y.; Sugino, K.; Itakura, H.; Hirota, M.; Yasumoto, T. Comparative studies on paralytic 
shellfish toxin profile of dinoflagellates and bivalves. In Toxic Marine Phytoplankton; Grane'li, Mar. Drugs 2010, 8  
 
 
2207 
E., Sundstrom, B., Edler, L., Anderson, D.M., Eds.; Elsevier Science Publishing: New York, NY, 
USA, 1990; pp. 391–396. 
85.  Vale,  P.  Complex  profiles  of  hydrophobic  paralytic  shellfish  poisoning  compounds  in 
Gymnodinium catenatum identified by liquid chromatography with fluorescence detection and 
mass spectrometry. J. Chromatogr. A 2008, 1195, 85–93. 
86.  Vale,  P.;  Rangel,  I.;  Silva,  B.;  Coelho,  P.;  Vilar,  A.  Atypical  profiles  of  paralytic  shellfish 
poisoning  toxins  in  shellfish  from  Luanda  and  Mussulo  bays,  Angola.  Toxicon  2009,  53,  
176–183. 
87.  Arakawa, O.; Nishio, S.; Noguchi, T.; Shida, Y.; Onoue, Y. A new saxitoxin analogue from a 
xanthid crab Atergatis floridus. Toxicon 1995, 33, 1577–1584. 
88.  Zaman, L.; Arakawa, O.; Shimosu, A.; Shida, Y.; Onoue, Y. Occurrence of a methyl derivative 
of saxitoxin in Bangladeshi freshwater puffers. Toxicon 1998, 36, 627–630. 
89.  Yotsu-Yamashita, M.; Kim, Y.H.; Dudley, S.C.; Choudhary, G.; Pfahnl, A.; Oshima, Y.; Daly, 
J.W.  The  structure  of  zetekitoxin  AB,  a  saxitoxin  analog  from  the  Panamanian  golden  frog 
Atelopus  zeteki:  A  potent  sodium-channel  blocker.  Proc.  Natl.  Acad.  Sci.  USA  2004,  101,  
4346–4351. 
90.  van  Apeldoorn,  M.E.;  van  Egmond,  H.P.;  Speijers,  G.J.A.;  Bakker,  G.J.I.  Toxins  of 
cyanobacteria. Mol. Nutr. Food Res. 2007, 51, 7–60. 
91.  Negri, A.P.; Bolch, C.J.; Blackbum, S.I.; Dickman, M.; Llewellyn, L.E.; Mendez, S. Paralytic 
shellfish toxins in Gymnodinium catenatum strains from six countries. In Harmfull Algal Blooms 
2000;  Hallegraeff,  G.,  Bolch,  C.J.,  Blackburn,  S.I.,  Lewis,  R.J.,  Eds.;  Intergovernmental 
Oceanographic Commission of UNESCO: Paris, France, 2001; pp. 210–213. 
92.  Llewellyn, L.; Negri, A.; Quilliam, M. High affinity for the rat brain sodium channel of newly 
discovered  hydroxybenzoate  saxitoxin  analogues  from  the  dinoflagellate  Gymnodinium 
catenatum. Toxicon 2004, 43, 101–104. 
93.  Vale, P. Fate of benzoate paralytic shellfish poisoning toxins from Gymnodinium catenatum in 
shellfish and fish detected by pre-column oxidation and liquid chromatography with fluorescence 
detection. J. Chromatogr. A 2008, 1190, 191–197. 
94.  Codd, G.A.; Morrison, L.F.; Metcalf, J.S. Cyanobacterial toxins: risk management for health 
protection. Toxicol. Appl. Pharm. 2005, 203, 264–272. 
95.  Usleber, E.; Donald, M.; Straka, M.; Mä rtlbauer, E. Comparison of enzyme immunoassay and 
mouse bioassay for determining paralytic shellfish poisoning toxins in shellfish.  Food Addit. 
Contam. 1997, 14, 193–198. 
96.  Genenah, A.A.; Shimizu, Y. Specific toxicity of paralytic shellfish poisons. J. Agr. Food Chem. 
1981, 29, 1289–1291. 
97.  Sullivan, J.J.; Wekell, M.M.; Kentala, L.L. Application of HPLC for the Determination of PSP 
Toxins in Shellfish. J. Food Sci. 1985, 50, 26–29. 
98.  Oshima,  Y.;  Sugino,  K.;  Yasumoto,  T.  Mycotoxins  and  Phycotoxins  '88;  Elsevier  Applied 
Science: Amsterdam, The Netherlands, 1989. 
99.  Oshima,  Y.  Chemical  and  enzymatic  transformation  of  paralytic  shellfish  toxins  in  marine 
organisms.  In  Harmful  Marine  Algal  Blooms;  Lassus,  P.,  Arzul,  G.,  Erard,  E.,  Gentien,  P., 
Marcaillou, C., Eds.; Lavoisier: Paris, France, 1995. Mar. Drugs 2010, 8  
 
 
2208 
100.  Asakawa, M.; Miyazawa, K.; Takayama, H.; Noguchi, T. Dinoflagellate Alexandrium tamarense 
as the source of paralytic shellfish poison (PSP) contained in bivalves from Hiroshima Bay, 
Hiroshima Prefecture, Japan. Toxicon 1995, 33, 691–697. 
101.  Bricelj, V.M.; Lee, J.H.; Cembella, A.D. Influence of dinoflagellate cell toxicity on uptake and 
loss of paralytic shellfish toxins in the northern quahog  Mercenaria mercenaria. Mar. Ecol. 
Prog. Ser. 1991, 74, 33–46. 
102.  Bricelj, V.M.; Lee, J.H.; Cembella, A.D.; Anderson, D.M. Uptake kinetics of paralytic shellfish 
toxins from the dinoflagellate Alexandrium fundyense in the mussel Mytilus edulis. Mar. Ecol. 
Prog. Ser. 1990, 63, 177–188. 
103.  Cembella,  A.D.;  Shumway,  S.E.;  Lewis,  N.I.  Anatomical  distribution  and  spatio-temporal 
variation in paralytic shellfish toxin composition in two bivalve species from the Gulf of Maine. 
J. Shellfish Res. 1993, 12, 389–403. 
104.  Lassus, P.; Bardouill, M.; Massselin, P.; Naviner, P.; Truquet., P. Comparative efficiencies of 
different non-toxic microalgal diets in detoxification of PSP-contaminated oysters (Crassoatrea 
gigas Thunberg). J. Nat. Toxins 2000, 9, 1–12. 
105.  Oshima, Y.; Fallon, W.E.; Shimizu, Y.; Noguchi, T.; Hashimoto, Y. Toxins of the Gonyaulax sp. 
and infested bivalves in Owase Bay. Bull. Jpn. Soc. Sci. Fish. 1976, 42, 851–856. 
106.  Sullivan, J.J.; Iwaoka, W.T.; Liston, J. Enzymatic transformation of PSP toxins in the littleneck 
clam (Protothaca staminea). Biochem. Biophys. Res. Commun. 1983, 114, 465–472. 
107.  Shimizu,  Y.;  Yoshioka,  M.  Transformation  of  paralytic  shellfish  toxins  as  demonstrated  in 
scallop homogenates. Science 1981, 212, 547–549. 
108.  Lu,  Y.;  Hwang,  D.  Effects  of  toxic  dinoflagellates  and  toxin  biotransformation  in  bivalves.  
J. Nat. Toxins 2002, 11, 315–322. 
109.  Fast, M.D.; Cembella, A.D.; Ross, N.W. In vitro transformation of paralytic shellfish toxins in 
the clams Mya arenaria and Protothaca staminea. Harmful Algae 2006, 5, 79–90. 
110.  Kotaki, Y.; Oshima, Y.; Yasumoto, T. Bacterial transformation of paralytic shellfish toxins in 
coral reef crabs and a marine snail. Nippon Suisan Gakk. 1985, 51, 1009–1013  
111.  Kotaki, Y. Screening of bacteria which convert gonyautoxin 2,3 to saxitoxin.  Nippon Suisan 
Gakk. 1989, 55, 1293. 
112.  Sugawara, A.; Imamura, T.; Aso, S.; Ebitani, K. Change of paralytic shellfish poison by the 
marine bacteria living in the intestine of the Japanese surf clam, Pseudocardium sybillae, and the 
brown sole, Pleuronectes herensteini. Sci. Rep. Hokkaido Fish. Exp. Stat. 1997, 50, 35–42. 
113.  Smith, E.A.; Grant, F.; Ferguson, C.M.J.; Gallacher, S. Biotransformations of paralytic shellfish 
toxins  by  bacteria  isolated  from  bivalve  molluscs.  Appl.  Environ.  Microbiol.  2001,  67,  
2345–2353. 
114.  Donovan,  C.J.;  Garduno,  R.A.;  Kalmokoff,  M.;  Ku,  J.C.;  Quilliam,  M.A.;  Gill,  T.A. 
Pseudoalteromonas bacteria are capable of degrading paralytic shellfish toxins. Appl. Environ. 
Microbiol. 2009, 75, 6919–6923. 
115.  Donovan, C.J.; Ku, J.C.; Quilliam, M.A.; Gill, T.A. Bacterial degradation of paralytic shellfish 
toxins. Toxicon 2008, 52, 91–100. 
116.  Kayal, N.; Newcombe, G.; Ho, L. Investigating the fate of saxitoxins in biologically active water 
treatment plant filters. Environ. Toxicol. 2008, 23, 751–755. Mar. Drugs 2010, 8  
 
 
2209 
117.  Garcí a,  C.;  Rodriguez-Navarro,  A.;  Dí az,  J.C.;  Torres,  R.;  Lagos,  N.  Evidence  of  in  vitro 
glucuronidation and enzymatic transformation of paralytic shellfish toxins by healthy human 
liver microsomes fraction. Toxicon 2009, 53, 206–213. 
118.  Andrinolo,  D.;  Michea,  L.F.;  Lagos,  N.  Toxic  effects,  pharmacokinetics  and  clearance  of 
saxitoxin, a component of paralytic shellfish poison (PSP), in cats. Toxicon 1999, 37, 447–464. 
119.  Kasper, B.C.; Henton, D. Glucuronidation. In Enzymatic Basis of Detoxication; Jakob, W.B., Ed.; 
Academic: New York, NY, USA, 1960; Vol. 1. 
120.  Stafford, R.G.; Hines, H.B. Urinary elimination of saxitoxin after intravenous injection. Toxicon 
1995, 33, 1501–1510. 
121.  Hines, H.; Naseem, S.; Wannemacher, R.J. 3H-Saxitoxinol metabolism and elimination in the rat. 
Toxicon 1993, 31, 905–908. 
122.  Gessner, B.D.; Bell, P.; Doucette, G.J.; Moczydlowski, E.; Poli, M.A.; Van Dolah, F.; Hall, S. 
Hypertension and identification of toxin in human urine and serum following a cluster of mussel-
associated paralytic shellfish poisoning outbreaks. Toxicon 1997, 35, 711–722. 
123.  Johnson, R.C.; Zhou, Y.; Statler, K.; Thomas, J.; Cox, F.; Hall, S.; Barr, J.R. Quantification of 
saxitoxin and neosaxitoxin in human urine utilizing isotope dilution tandem mass spectrometry. 
J. Anal. Toxicol. 2009, 33, 8–14. 
124.  Kellmann, R.; Neilan, B.A. Biochemical characterization of paralytic shellfish toxin biosynthesis 
in vitro. J. Phycol. 2007, 43, 497–508. 
125.  Mihali, T.K.; Carmichael, W.W.; Neilan, B.A. Biosynthesis of the Lyngbya wollei (Farlow ex 
Gomont) paralytic shellfish toxins - natural biocombinatorics. PLoS One 2010, Submitted for 
publication. 
126.  Prol, M.J.; Guisande, C.; Barreiro, A.; Miguez, B.; de la Iglesia, P.; Villar, A.; Gago-Martinez, 
A.;  Combarro,  M.P.  Evaluation  of  the  production  of  paralytic  shellfish  poisoning  toxins  by 
extracellular  bacteria  isolated  from  the  toxic  dinoflagellate  Alexandrium  minutum.  Can.  J. 
Microbiol. 2009, 55, 943–954. 
127.  Baker,  T.R.;  Doucette,  G.J.;  Powell,  C.L.;  Boyer,  G.L.;  Plumley,  F.G.  GTX4  imposters: 
Characterization  of  fluorescent  compounds  synthesized  by  Pseudomonas  stutzeri  SF/PS  and 
Pseudomonas/Alteromonas PTB-1, symbionts of saxitoxin-producing Alexandrium spp. Toxicon 
2003, 41, 339–347. 
128.  Gallacher, S.; Flynn, K.; Franco, J.; Brueggemann, E.; Hines, H. Evidence for production of 
paralytic shellfish toxins by bacteria associated with Alexandrium spp. (Dinophyta) in culture. 
Appl. Environ. Microbiol. 1997, 63, 239–245. 
129.  Moustafa,  A.;  Loram,  J.E.;  Hackett,  J.D.;  Anderson,  D.M.;  Plumley,  F.G.;  Bhattacharya,  D. 
Origin of saxitoxin biosynthetic genes in cyanobacteria. PLoS ONE 2009, 4, e5758. 
130.  Hill,  A.M.  The  biosynthesis,  molecular  genetics  and  enzymology  of  the  polyketide-derived 
metabolites. Nat. Prod. Rep. 2006, 23, 256–320. 
131.  Wolf, E.; Vassilev, A.; Makino, Y.; Sali, A.; Nakatani, Y.; Burley, S.K. Crystal Structure of a 
GCN5-Related N-acetyltransferase: Serratia marcescens Aminoglycoside 3-N-acetyltransferase. 
Cell 1998, 94, 439–449. Mar. Drugs 2010, 8  
 
 
2210 
132.  Kagan,  R.M.;  Clarke,  S.  Widespread  occurrence  of  three  sequence  motifs  in  diverse  
S-adenosylmethionine-dependent  methyltransferases  suggests  a  common  structure  for  these 
enzymes. Arch. Biochem. Biophys. 1994, 310, 417–427. 
133.  Alexander, F.W.; Sandmeier, E.; Mehta, P.K.; Christen, P. Evolutionary relationships among 
pyridoxal-5'-phosphate-dependent enzymes. Eur. J. Biochem. 1994, 219, 953–960. 
134.  Alexander, D.C.; Jensen, S.E. Investigation of the Streptomyces clavuligerus cephamycin C gene 
cluster and its regulation by the CcaR protein. J. Bacteriol. 1998, 180, 4068–4079. 
135.  Yoshida,  T.;  Sako,  Y.;  Uchida,  A.;  Kakutani,  T.;  Arakawa,  O.;  Noguchi,  T.;  Ishida,  Y. 
Purification and characterization of sulfotransferase specific to O-22 of 11-hydroxy saxitoxin 
from  the  toxic  dinoflagellate  Gymnodinium  catenatum  (dinophyceae).  Fish.  Sci.  2002,  68,  
634–642. 
136.  Sako,  Y.;  Yoshida,  T.;  Uchida,  A.;  Arakawa,  O.;  Noguchi,  T.;  Ishida,  Y.  Purification  and 
characterization of a sulfotransferase specific to N-21 of saxitoxin and gonyautosin 2+3 from the 
toxic dinoflagellate Gymnodinium catenatum (Dinophyceae) J. Phycol. 2001, 37, 1044–1051. 
137.  Shimizu, Y. Microalgal metabolites. Chem. Rev. 1993, 93, 1685–1698. 
138.  Harlow, L.D.; Koutoulis,  A.;  Hallegraeff, G.M. S-adenosylmethionine synthetase genes from 
eleven marine dinoflagellates. Phycologia 2007, 46, 46–53. 
139.  Altschul, S.F.; Madden, T.L.; Schaffer, A.A.; Zhang, J.; Zhang, Z.; Miller, W.; Lipman, D.J. 
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic 
Acids Res. 1997, 25, 3389–3402. 
140.  Kellmann, R.; Mihali, T.K.; Neilan, B.A. Identification of a saxitoxin biosynthesis gene with a 
history of frequent horizontal gene transfers. J. Mol. Evol. 2008, 67, 526–538. 
141.  Yang,  I.;  John,  U.;  Beszteri,  S.;  Glockner,  G.;  Krock,  B.;  Goesmann,  A.;  Cembella,  A. 
Comparative  gene  expression  in  toxic  versus  non-toxic  strains  of  the  marine  dinoflagellate 
Alexandrium minutum. BMC Genomics 2010, 11, 248. 
142.  Halai,  R.;  Craik,  D.J.  Conotoxins:  Natural  product  drug  leads.  Nat.  Prod.  Rep.  2009,  26,  
526–536. 
143.  Klotz,  U.  Ziconotide—a  novel  neuron-specific  calcium  channel  blocker  for  the  intrathecal 
treatment  of  severe  chronic  pain—a  short  review.  Int.  J.  Clin.  Pharmacol.  Ther.  2006,  44,  
478–483. 
144.  Glaser, K.B.; Mayer, A.M.S. A renaissance in marine pharmacology: From preclinical curiosity 
to clinical reality. Biochem. Pharmacol. 2009, 78, 440–448. 
145.  Olivera, B.M.; Cruz, L.J.; de Santos, V.; LeCheminant, G.W.; Griffin, D.; Zeikus, R.; McIntosh, 
M.;  Galyean,  R.;  Varga,  J.;  Gray,  W.R.;  Rivier,  J.  Neuronal  calcium  channel  antagonists. 
Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus 
venom. Biochemistry 1987, 26, 2086–2090. 
146.  Molinski, T.F.; Dalisay, D.S.; Lievens, S.L.; Saludes, J.P. Drug development from marine natural 
products. Nat. Rev. Drug Discov. 2009, 8, 69–85. 
147.  Kohane, D.S.; Yieh, J.; Lu, N.T.; Langer, R.; Strichartz, G.R.; Berde, C.B. A re-examination of 
tetrodotoxin for prolonged duration local anesthesia. Anesthesiology 1998, 89, 119–131. 
148.  Barnet, C.S.; Tse, J.Y.; Kohane, D.S. Site 1 sodium channel blockers prolong the duration of 
sciatic nerve blockade from tricyclic antidepressants. Pain 2004, 110, 432–438. Mar. Drugs 2010, 8  
 
 
2211 
149.  Kohane, D.S.; Lu, N.T.; Gö kgö l-Kline, A.C.; Shubina, M.; Kuang, Y.; Hall, S.; Strichartz, G.R.; 
Berde, C.B. The local anesthetic properties and toxicity of saxitonin homologues for rat sciatic 
nerve block in vivo. Reg. Anesth. Pain Med. 2000, 25, 52–59. 
150.  Epstein-Barash, H.; Shichor, I.; Kwon, A.H.; Hall, S.; Lawlor, M.W.; Langer, R.; Kohane, D.S. 
Prolonged duration local anesthesia with minimal toxicity. Proc. Natl. Acad. Sci. USA 2009, 106, 
7125–7130. 
151.  Chorny,  M.;  Levy,  R.J.  Site-specific  analgesia  with  sustained  release  liposomes.  Proc.  Natl. 
Acad. Sci. USA 2009, 106, 6891–6892. 
152.  Garrido, R.; Lagos, N.; Lattes, K.; Azolas, C.G.; Bocic, G.; Cuneo, A.; Chiong, H.; Jensen, C.; 
Henriquez, A.I.; Fernandez, C. The gonyautoxin 2/3 epimers reduces anal tone when injected in 
the anal sphincter of healthy adults. Biol. Res. 2004, 37, 395–403. 
153.  Garrido, R.; Lagos, N.; Lattes, K.; Abedrapo, M.; Bocic, G.; Cuneo, A.; Chiong, H.; Jensen, C.; 
Azolas, R.; Henriquez, A.; Garcia, C. Gonyautoxin: New treatment for healing acute and chronic 
anal fissures. Dis. Colon Rectum 2005, 48, 335–343. 
154.  Garrido, R.; Lagos, N.; Lagos, M.; Rodrí guez-Navarro, A.J.; Garcia, C.; Truan, D.; Henriquez, 
A. Treatment of chronic anal fissure by gonyautoxin. Colorectal Dis. 2007, 9, 619–624. 
155.  Eisenhammer, S. The surgical correction of chronic internal anal (sphincteric) contracture. S. Afr. 
Med. J. 1951, 25, 486–489. 
156.  Khubchandani, I.T.; Reed, J.F. Sequelae of internal sphincterotomy for chronic fissure in ano. 
Br. J. Surg. 1989, 76, 431–434. 
157.  Hsu, T.-C.; MacKeigan, J. Surgical treatment of chronic anal fissure. Dis. Colon Rectum 1984, 
27, 475–478. 
158.  Ezri, T.; Susmallian, S. Topical nifedipine vs. topical glyceryl trinitrate for treatment of chronic 
anal fissure. Dis. Colon Rectum 2003, 46, 805–808. 
159.  Maria, G.; Brisinda, G.; Bentivoglio, A.R.; Cassetta, E.; Gui, D.; Albanese, A. Botulinum toxin 
injections  in  the  internal  anal  sphincter for the treatment of chronic anal fissure: Long-term 
results after two different dosage regimens. Ann. Surg. 1998, 228, 664–669. 
160.  Gorfine, S.R. Topical nitroglycerin therapy for anal fissures and ulcers. N. Engl. J. Med. 1995, 
333, 1156–1157. 
161.  Lattes, K.; Venegas, P.; Lagos, N.; Lagos, M.; Pedraza, L.; Rodriguez-Navarro, A.J.; Garcia, C. 
Local  infiltration  of  gonyautoxin  is  safe  and  effective  in  treatment  of  chronic  tension-type 
headache. Neurol. Res. 2009, 31, 228–233. 
162.  Yan, T.; Fu, M.; Li, J.; Yu, R.; Zhou, M. Accumulation, transformation and elimination of PSP in 
Mytilus edulis. Oceanol. Limnol. Sin. 2001, 32, 421–427. 
Samples Availability: Available from the authors. 
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 